Abstract
Background and aims Inhibitors of apolipoprotein C-III (apoC3) are currently approved for the reduction of triglyceride levels in patients with Familial Chylomicronemia Syndrome. We used drug target Mendelian randomization (MR) to assess the effect of genetically predicted decrease in APOC3 blood protein levels on cardiometabolic traits and diseases.
Methods We quantified lifelong reductions in APOC3 blood levels by selecting all genome wide significant and independent (r2<0.1) single nucleotide polymorphisms (SNPs) in the APOC3 gene region ±1Mb, from three genome-wide association studies (GWAS) of apoC3 blood protein levels (deCODE, n = 35,378, Fenland, n = 10,708 and ARIC, n = 7,213). We included the largest GWASes on 18 cardiometabolica traits and 9 cardiometabolic diseases as study outcomes.
Results A one standard deviation lowering in apoC3 blood protein levels was associated with lower triglycerides, apolipoprotein B, density lipoprotein cholesterol, alanine aminotransferase, and glomerular filtration rate as well as higher high-density lipoprotein cholesterol levels. APOC3 lowering was also associated with lower risk of acute pancreatitis (odds ratio [OR] = 0.91 95% CI=0.82 to 1.00), aortic stenosis (OR = 0.82 95% CI=0.73 to 0.93), and coronary artery disease (OR = 0.86 95% CI=0.80 to 0.93), and was associated with increased parental lifespan (0.06 95% CI=0.03 to 0.09 years). These results were concordant across robust MR methods, the three protein datasets and upon adjustment for APOA1, APOA4 and APOA5 using a multivariable MR framework.
Conclusions These results provide evidence that apoC3 lowering could result in widespread benefits for cardiometabolic health and encourage the launch of trials on apoC3 inhibition for coronary artery disease prevention.
Competing Interest Statement
BJA is a consultant for Novartis, Eli Lilly, Editas Medicine and Silence Therapeutics and has received research contracts from Pfizer, Eli Lilly and Silence Therapeutics.
Funding Statement
EG holds a doctoral research award from the Fonds de recherche du Quebec: Sante. (FRQS). BJA holds a senior scholar awards from the FRQS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in the present study were openly available. Relevant information to retrieve the summary statistics can be retrieved in supplementary table 1.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
